3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
61
HER2-positive Breast Cancer
10
Neoplasm Metastasis
5
Ovarian Neoplasms
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
3
Solid Tumor
2
Prostatic Neoplasms
2
Endometrial Neoplasms
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Tumors
1
Solid Cancers
1
Solid Cancer
1
Resectable HER2-positive Breast Cancer
1
Recurrence
1
Patient Preference
1
Neoplasms, Unknown Primary
1
Lung Neoplasms
1
Liver Neoplasms
1
Inflammatory Breast Neoplasms
1
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Early-stage or Locally Advanced HER2-positive Breast Cancer
1
Early or Locally Advanced HER2-positive Breast Cancer
1
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Unresectable or Metastatic Solid Malignancy
×
pertuzumab
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts